P. Walter and D. Ron, The unfolded protein response: from stress pathway to homeostatic regulation, Galway, Galway H91 TK33, Ireland. 4 2bind GmbH, vol.11, pp.1081-1086, 2011.

G. E. Karagoz, An unfolded protein-induced conformational switch activates mammalian IRE1, Elife, vol.6, p.30700, 2017.

R. Sano and J. C. Reed, ER stress-induced cell death mechanisms, Biochim. Biophys. Acta, vol.1833, pp.3460-3470, 2013.

H. P. Harding, Regulated translation initiation controls stress-induced gene expression in mammalian cells, Mol. Cell, vol.6, pp.1099-1108, 2000.

J. M. Axten, Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), J. Med. Chem, vol.55, pp.7193-7207, 2012.

M. Halliday, Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity, Cell Death Dis, vol.6, p.1672, 2015.

D. Rojas-rivera, When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157, Cell Death Differ, vol.24, pp.1100-1110, 2017.

R. Ghosh, Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress, Cell, vol.158, pp.534-548, 2014.

S. Ranatunga, Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity, J. Med. Chem, vol.57, pp.4289-4301, 2014.

K. Stankov, S. Popovic, and M. Mikov, C-KITsignaling in cancer treatment, Curr. Pharm. Des, vol.20, pp.2849-2880, 2014.

J. G. Doench, Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9, Nat. Biotechnol, vol.34, pp.184-191, 2016.

L. Cong, Multiplex genome engineering using CRISPR/Cas systems, Science, vol.339, pp.819-823, 2013.

C. Zhang, Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor, Proc. Natl. Acad. Sci. USA, vol.110, pp.5689-5694, 2013.

V. Capone, PERK inhibition attenuates the abnormalities of the secretory pathway and the increased apoptotic rate induced by SIL1 knockdown in HeLa cells, Biochim. Biophys. Acta, vol.1864, pp.3164-3180, 2018.

L. Augusto, J. Martynowicz, K. A. Staschke, R. C. Wek, and W. J. Sullivan, Effects of PERK eIF2alpha kinase Inhibitor against Toxoplasma gondii, Antimicrob. Agents Chemother, vol.62, pp.1442-1460, 2018.

D. Y. Dadey, V. Kapoor, A. Khudanyan, D. Thotala, and D. E. Hallahan, PERK regulates glioblastoma sensitivity to ER stress although promoting radiation resistance, Mol. Cancer Res, vol.16, pp.1447-1453, 2018.

M. C. Heinrich, Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor, Blood, vol.96, pp.925-932, 2000.

C. D. Mol, Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase, J. Biol. Chem, vol.279, pp.31655-31663, 2004.

V. Perfetti, Molecular and functional characterization of a new 3? end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant imatinib, Oncotarget, vol.8, pp.56158-56167, 2017.

N. P. Shah, Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study, Blood, vol.123, pp.2317-2324, 2014.

M. M. Schittenhelm, Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies, Cancer Res, vol.66, pp.473-481, 2006.

A. L. Smith, Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK), J. Med. Chem, vol.58, pp.1426-1441, 2015.

D. Pytel, PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma, PLoS Genet, vol.12, p.1006518, 2016.

K. V. Gleixner, PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects, Blood, vol.107, pp.752-759, 2006.

A. Tobio, A. Alfonso, and L. M. Botana, C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCdelta translocation in HMC-1(560) and HMC-1(560,816) cell lines, Immunopharmacol. Immunotoxicol, vol.37, pp.380-387, 2015.

D. J. Lamb, BI 1002494, a novel potent and selective oral spleen tyrosine kinase inhibitor, displays differential potency in human basophils and B cells, J. Pharmacol. Exp. Ther, vol.357, pp.554-561, 2016.

M. Kozlowski, SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain, Mol. Cell. Biol, vol.18, pp.2089-2099, 1998.

D. B. Lipka, Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells, PLoS ONE, vol.7, p.40853, 2012.

A. R. Finch, C. J. Caunt, S. P. Armstrong, and C. A. Mcardle, Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors, Am. J. Physiol. Cell Physiol, vol.297, pp.591-600, 2009.

J. Bakker, M. Spits, J. Neefjes, and I. Berlin, The EGFR odyssey-from activation to destruction in space and time, J. Cell Sci, vol.130, pp.4087-4096, 2017.

K. W. Cho, Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide, Oncogene, vol.32, pp.1018-1029, 2013.

M. J. Clague, Met receptor: a moving target, Sci. Signal, vol.4, p.40, 2011.

S. Rai, Clathrin assembly protein CALM plays a critical role in KIT signaling by regulating its cellular transport from early to late endosomes in hematopoietic cells, PLoS ONE, vol.9, p.109441, 2014.

T. Jahn, Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain, Oncogene, vol.21, pp.4508-4520, 2002.

S. K. Heo, Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death, Sci. Rep, vol.7, p.15278, 2017.

S. Morita, Targeting ABL-IRE1alpha signaling spares ER-stressed pancreatic beta cells to reverse autoimmune diabetes, Cell Metab, vol.25, pp.883-897, 2017.